

Apple. No. : 08/779,767
Filed : January 7, 1997

In The Claims:

Claims 4, 6, 9, 11, 24, 26, 27, 29, 66 - 70 and 72 - 74 are pending in the application. Claims 4, 6, 9, 11, 24, 26, 27, 29, 66 - 70, 73 and 74 have been indicated as allowable. Claim 72 is objected to. Please amend claim 72 as follows:

1. (canceled).
2. (canceled).
3. (canceled).
4. (previously presented) The composition of Claim 66 wherein said T cell receptor antagonist derived from proteolipid protein is a peptide analog of proteolipid protein.
5. (canceled).
6. (previously presented) The composition of Claim 66 wherein said immunoglobulin or portion thereof comprises at least part of a domain of a constant region of an immunoglobulin molecule.
7. (canceled).
8. (canceled).
9. (previously presented) The composition of Claim 66 wherein the composition comprises a fusion protein in which said protein fragment or peptide comprising a T cell receptor antagonist is covalently joined to said immunoglobulin or portion thereof.
10. (canceled).

Apple. No. : 08/779,767
Filed : January 7, 1997

11. (previously presented) The composition of Claim 9 wherein the protein fragment or peptide comprising said T cell receptor antagonist is positioned within at least one complementarity determining region to partially or fully replace said complementarity determining region.

12. (canceled).

13. (canceled).

14. (canceled).

15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled),

19. (canceled).

20. (canceled).

21. (canceled).

22. (canceled).

23. (canceled).

Apple. No. : 08/779,767
Filed : January 7, 1997

24. (previously presented) The composition of claim 66 wherein said protein fragment or peptide comprising a T cell receptor antagonist comprises a peptide analog of a peptide which induces a T cell response.
25. (canceled).
26. (previously presented) The composition of claim 67 wherein said immunoglobulin or portion thereof comprises at least part of one domain of a constant region of an immunoglobulin molecule.
27. (previously presented) The composition of claim 26 wherein the immunoglobulin or portion thereof is a human IgG molecule or portion thereof.
28. (canceled).
29. (previously presented) The composition of claim 27 wherein said composition comprises a fusion protein in which said protein fragment or peptide comprising a T cell receptor antagonist is covalently joined to said immunoglobulin or portion thereof.
30. (canceled).
31. (canceled).
32. (canceled).
33. (canceled).
34. (canceled).

Apple. No. : 08/779,767
Filed : January 7, 1997

35. (canceled).

36. (canceled).

37. (canceled).

38. (canceled).

39. (canceled).

40. (canceled).

41. (canceled).

42. (canceled).

43. (canceled).

44. (canceled).

45. (canceled).

46. (canceled).

47. (canceled).

48. (canceled).

49. (canceled).

Apple. No. : 08/779,767
Filed : January 7, 1997

50. (canceled).

51. (canceled).

52. (canceled).

53. (canceled).

54. (canceled).

55. (canceled).

56. (canceled).

57. (canceled).

58. (canceled).

59. (canceled).

60. (canceled).

61. (canceled).

62. (canceled).

63. (canceled).

Apple. No. : 08/779,767
Filed : January 7, 1997

64. (canceled).

65. (canceled).

66. (previously presented) A composition comprising an immunoglobulin or a portion thereof linked to a protein fragment or peptide, wherein said immunoglobulin or portion thereof is capable of binding to an Fc receptor and said protein fragment or peptide comprises a T cell receptor antagonist, said composition having the property of being endocytosed by cells bearing said Fc receptor and processed by the cells to present said T cell receptor antagonist in association with endogenous MHC Class II molecules, thereby preventing activation of autoreactive T cells *in vivo*.

67. (previously presented) The composition of Claim 66, further comprising a pharmaceutically acceptable carrier.

68. (previously presented) The composition of Claim 66, wherein said protein fragment or peptide comprising a T cell receptor antagonist is covalently linked to said immunoglobulin or portion thereof.

69. (previously presented) The composition of Claim 68, wherein said protein fragment or peptide comprising a T cell receptor antagonist comprises a peptide analog of proteolipid protein.

70. (previously presented) The composition of Claim 68, wherein said immunoglobulin or portion thereof comprises at least part of a domain of a constant region of an immunoglobulin molecule.

71. (canceled).

Apple. No. : 08/779,767
Filed : January 7, 1997

72. (currently amended) The composition of Claim 67, ~~wherein~~ wherein the composition comprises a fusion protein in which said protein fragment or peptide comprising a T cell receptor antagonist is covalently joined to said immunoglobulin or portion thereof.

73. (currently amended) The composition of Claim 72, wherein said protein fragments or peptide comprising a T cell receptor antagonist is positioned within at least one ~~complementary~~ complementarity determining region to partially or fully replace said complementarity determining region.

74. (previously presented) The composition of Claim 66, wherein said T cell receptor antagonist is derived from proteolipid protein.

75. (canceled).